Literature DB >> 18071314

Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis.

M S Frech1, K M Torre, G W Robinson, P A Furth.   

Abstract

We have previously shown that increased and deregulated estrogen receptor alpha expression in the mammary gland leads to the development of proliferative disease and cancer. To address the importance of cyclin D1 in ERalpha-mediated mammary tumorigenesis, we crossed ERalpha-overexpressing mice with cyclin D1 knockout mice. Mammary gland morphogenesis was completely interrupted in the ERalpha-overexpressing cyclin D1-deficient triple transgenic mice. In addition to a highly significant reduction in mammary epithelial cell proliferation, cyclin E was upregulated resulting in DNA damage checkpoint activation and apoptosis. This imbalance between proliferative and apoptotic rates in conjunction with remarkable structural defects and cellular disorganization in the terminal end buds interrupted ductal morphogenesis. Interestingly, the structure of the mammary fat pad was fundamentally altered by the consequences of overexpressing ERalpha in the epithelial cells in the absence of cyclin D1 illustrating how alterations in the epithelial compartment can impact surrounding stromal composition. Transplantation of embryonic ERalpha-overexpressing and cyclin D1-deficient mammary epithelium into the cleared fat pad of wild-type mice did not rescue the aberrant mammary gland phenotype indicating that it was intrinsic to the mammary epithelial cells. In conclusion, although cyclin D1 is not essential for proliferation of normal mammary epithelial cells, ERalpha-overexpressing cells are absolutely dependent on cyclin D1 for proliferation. This differential requirement for cyclin D1 in normal vs abnormal mammary epithelial cells supports the application of cyclin D1 inhibitors as therapeutic interventions in ERalpha-overexpressing breast cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18071314      PMCID: PMC7007637          DOI: 10.1038/sj.onc.1210974

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Stromal effects on mammary gland development and breast cancer.

Authors:  Bryony S Wiseman; Zena Werb
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

2.  Deregulated cyclin E induces chromosome instability.

Authors:  C H Spruck; K A Won; S I Reed
Journal:  Nature       Date:  1999-09-16       Impact factor: 49.962

3.  Cyclin E and survival in patients with breast cancer.

Authors:  Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

4.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

5.  Oestrogen receptor expression in the normal and pre-cancerous breast.

Authors:  B S Shoker; C Jarvis; D R Sibson; C Walker; J P Sloane
Journal:  J Pathol       Date:  1999-07       Impact factor: 7.996

6.  Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ.

Authors:  M Silvina Frech; Ewa D Halama; Maddalena T Tilli; Baljit Singh; Edward J Gunther; Lewis A Chodosh; Jodi A Flaws; Priscilla A Furth
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

7.  Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.

Authors:  V Fantl; G Stamp; A Andrews; I Rosewell; C Dickson
Journal:  Genes Dev       Date:  1995-10-01       Impact factor: 11.361

Review 8.  Tumour-stromal interactions. Role of the stroma in mammary development.

Authors:  G B Silberstein
Journal:  Breast Cancer Res       Date:  2001-03-22       Impact factor: 6.466

9.  Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions.

Authors:  B S Shoker; C Jarvis; M P Davies; M Iqbal; D R Sibson; J P Sloane
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

10.  Deregulation of cyclin E in human cells interferes with prereplication complex assembly.

Authors:  Susanna Ekholm-Reed; Juan Méndez; Donato Tedesco; Anders Zetterberg; Bruce Stillman; Steven I Reed
Journal:  J Cell Biol       Date:  2004-06-14       Impact factor: 10.539

View more
  10 in total

Review 1.  Genetically engineered ERα-positive breast cancer mouse models.

Authors:  Sarah A Dabydeen; Priscilla A Furth
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

2.  Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland.

Authors:  Nadia Okolowsky; Priscilla A Furth; Paul A Hamel
Journal:  Dev Biol       Date:  2014-04-21       Impact factor: 3.582

Review 3.  Hormone-sensing mammary epithelial progenitors: emerging identity and hormonal regulation.

Authors:  Gerard A Tarulli; Geraldine Laven-Law; Reshma Shakya; Wayne D Tilley; Theresa E Hickey
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-09-21       Impact factor: 2.673

4.  Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.

Authors:  Qian Zhang; Kazuhito Sakamoto; Chengbao Liu; Aleata A Triplett; Wan-chi Lin; Hallgeir Rui; Kay-Uwe Wagner
Journal:  Cancer Res       Date:  2011-10-28       Impact factor: 12.701

5.  Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.

Authors:  Anne M Miermont; Angela R Parrish; Priscilla A Furth
Journal:  Carcinogenesis       Date:  2010-02-24       Impact factor: 4.944

Review 6.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

7.  Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Authors:  Rebecca E Nakles; Maddalena Tilli Shiffert; Edgar S Díaz-Cruz; M Carla Cabrera; Maram Alotaiby; Anne M Miermont; Anna T Riegel; Priscilla A Furth
Journal:  Mol Endocrinol       Date:  2011-02-03

8.  Mouse Mammary Gland Whole Mount Density Assessment across Different Morphologies Using a Bifurcated Program for Image Processing.

Authors:  Brendan L Rooney; Brian P Rooney; Vinona Muralidaran; Weisheng Wang; Priscilla A Furth
Journal:  Am J Pathol       Date:  2022-09-14       Impact factor: 5.770

Review 9.  Cytochrome P450: Implications for human breast cancer.

Authors:  Bin Luo; Dandan Yan; Honglin Yan; Jingping Yuan
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

10.  Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.

Authors:  Anne M Miermont; Marina Carla Cabrera; Silvina M Frech; Rebecca E Nakles; Edgar S Diaz-Cruz; Maddalena Tilli Shiffert; Priscilla A Furth
Journal:  Anat Physiol       Date:  2012-06-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.